Caraco markets generic Casodex tablets
DETROIT Caraco Pharmaceutical Labs has launched bicalutamide tablets on behalf of Sun Pharma.
Bicalutamide tablets are an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone analog for the treatment of Stage D2 metastatic carcinoma of the prostate. This generic version of bicalutamide 50-mg tablets is bioequivalent to Casodex, which is a registered trademark of the AstraZeneca group of companies.
Daniel H. Movens, Caraco’s CEO said, “We are pleased to add this product to our portfolio by launching bicalutamide tablets immediately to the marketplace. We continue to focus on working towards expanding our product offering as quickly and effectively as possible.”
According to IMS Data, Casodex had U.S. sales of approximately $314 million for the calendar year of 2008.
CVS Caremark renews distribution agreements
SAN FRANCISCO McKesson has renewed its distribution agreement to supply CVS Caremark with branded and generic drugs, the company announced on Monday.
“CVS Caremark’s decision to renew its agreement with McKesson is reflective of the trusted relationship between our two companies and the value McKesson has delivered to CVS Caremark over the years,” stated Paul Julian, EVP, group president for McKesson. “McKesson’s comprehensive supply chain solutions help CVS Caremark ensure the highest levels of product availability and product integrity, empowering CVS Caremark to provide outstanding pharmaceutical care and further strengthen its competitive position.”
In related news, the retail giant also announced that it has renewed its distribution agreement with Cardinal Health. CVS Caremark said Cardinal Health will supply pharmaceuticals to its national network of retail pharmacies through mid-2013.
“We have a long-standing partnership with CVS Caremark, and we are proud to continue this important relationship,” said George Barrett, vice chairman of Cardinal Health and CEO of the Healthcare Supply Chain Services segment. “The footprint of the agreement is expected to be fundamentally the same as our existing relationship.”
Additional terms of the agreement were not disclosed.
FDA rejects application of pain-relief drug
PALATINE, Ill. The Food and Drug Administration has rejected an approval application for a pain-relief drug.
Acura Pharmaceuticals and King Pharmaceuticals announced that the FDA had issued a letter turning down their application for Acurox (oxycodone HC1, USP and niacin, USP), an immediate-release drug designed to relieve moderate to severe pain.
The companies said the letter expressed concerns about the potential abuse deterrent benefits of the drug. One of the drug’s ingredients, oxycodone, is a opiate-derived controlled substance popular with drug abusers.